Unable to display view head.php file not found.
 
 

James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 20

Reduced time to first stroke

The Figure shows the primary results of RE-LY.[96] Dabigatran 150 bid (black line) had a statistically significantly lower probability of the composite endpoint of stroke and systemic embolism than did warfarin.  Dabigatran 110 mg bid (dark blue line) was non-inferior to warfarin (light blue line), with both of these latter two having a similar probability of endpoint events.

 Reiffel JA. Am J Med 2013; 126: 00-00.

Complete references for all slides

References

[96] Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

Unable to display view foot.php file not found.